Biosyent (RX) Lytham Partners Fall 2024 Investor Conference summary

Business overview and strategy

• Focuses on unique, innovative pharmaceutical products addressing unmet needs, primarily in Canada, with some international reach in over 20 markets.

• Operates a low-R&D model, licensing late-stage or approved products from global partners.

• Maintains a strong balance sheet with no debt, significant cash reserves, and a scalable commercial platform covering all of Canada.

• Emphasizes shareholder-friendly practices, including share buybacks, dividends, and a high level of insider ownership.

• Management is experienced, long-tenured, and holds a significant ownership stake.

Financial performance and growth

• Achieved 56 consecutive profitable quarters, with TTM revenue just under CAD 34 million and EBITDA near CAD 9 million.

• Return on equity stands at 21%, with strong EBITDA and net income margins.

• Recent quarter saw a 12% top-line increase, and six-month results showed 15% revenue growth and 26% EBITDA and net income growth.

• Paid quarterly dividends, increasing them by 12.5% year-over-year.

• Recognized among the top 50 TSX Venture life science companies.

Product portfolio and recent developments

• Launched three new products last year and in-licensed a new endocrinology product in June, aiming for a 2026 launch.

• Acquired global rights to Tibella, a hormone replacement therapy, enhancing margins and international opportunities.

• FeraMAX brand remains a key growth driver, named top iron supplement in Canada for nine years, with new products and lifecycle strategies in place.

• Additional assets like Folic and Gelclair, launched last year, are expected to contribute to future growth.

• Ongoing focus on in-licensing and acquisitions to expand the portfolio.